0001079973-21-000999.txt : 20211004 0001079973-21-000999.hdr.sgml : 20211004 20211004081024 ACCESSION NUMBER: 0001079973-21-000999 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210930 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211004 DATE AS OF CHANGE: 20211004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPGEN INC CENTRAL INDEX KEY: 0001293818 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 061614015 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37367 FILM NUMBER: 211301075 BUSINESS ADDRESS: STREET 1: 9717 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-813-1260 MAIL ADDRESS: STREET 1: 9717 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 opgen_8k.htm FORM 8-K
0001293818 false 0001293818 2021-09-30 2021-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

September 30, 2021
Date of Report (date of earliest event reported)

_________________

OpGen, Inc.

(Exact name of Registrant as specified in its charter)

_________________

Delaware

(State or other jurisdiction of incorporation or organization)

  

001-37367

(Commission

File Number)

  

06-1614015

(I.R.S. Employer
Identification Number)

9717 Key West Ave, Suite 100
Rockville, MD 20850
(Address of principal executive offices)(Zip code)

(240) 813-1260
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

_________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock OPGN The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
 

 

 

Item 8.01   —   Other Events.

On October 4, 2021, OpGen, Inc. (the “Company”) announced that on September 30, 2021, the Company received clearance from the U.S. Food and Drug Administration (“FDA”) of its 510(k) application for its Acuitas AMR Gene Panel test for use with bacterial isolates. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

 

Also, on October 4, 2021, the Company issued a press release announcing preliminary financial results for the quarter ended September 30, 2021.  The Company’s press release is filed as Exhibit 99.2 to this Current Report on Form 8-K.

 

Item 9.01 —   Financial Statements and Exhibits.

(d) Exhibits

 

99.1  Press Release, dated October 4, 2021.
99.2 Press Release dated October 4, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 
 
 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

             
Date: October 4, 2021   OpGen, Inc.
       
    By:  

/s/ Oliver Schacht PhD

        Name:   Oliver Schacht PhD
        Title:   Chief Executive Officer

 

 EX-99.1 2 ex99x1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

 

OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel

·OpGen’s Acuitas® AMR Gene Panel allows testing for a comprehensive panel of 28 genetic AMR markers in isolated bacterial colonies from 26 different pathogens
·An aid to clinicians in the management of patients with known or suspected antibiotic non-susceptible or resistant bacterial infections
·OpGen targets commercial launch of the Acuitas® AMR Gene Panel in the U.S. in Q4-2021

 

ROCKVILLE, Md., October 4, 2021 -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that it has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the Acuitas® AMR Gene Panel, and is finalizing preparations for its swift commercial launch in the U.S.

The Acuitas® AMR Gene Panel detects 28 genetic antimicrobial resistance (AMR) markers in isolated bacterial colonies from 26 different pathogens. We believe the panel provides clinicians with a valuable diagnostic tool that informs about potential antimicrobial resistance patterns early and supports appropriate antibiotic treatment decisions in this indication. The Acuitas® AMR Gene Panel expands the diagnostic capability of clinicians to rapidly and simultaneously test for select drugs in 9 classes of antibiotics, including aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, penicillins, polymyxins, sulfonamides, trimethoprim, and vancomycin, to aid in the identification of potentially antimicrobial-resistant organisms that might otherwise escape detection and hence can prevent prolonged inappropriate treatment of patients. Furthermore, we believe the Acuitas® AMR Gene Panel is the first FDA cleared molecular diagnostic panel that detects such a broad panel of AMR markers from isolates.

“Overcoming the challenges associated with antibacterial resistance begins with an understanding and knowledge of the pathogen’s genetic profile, especially a profile of relevant resistant genes they harbor,” commented Dr. James W. Snyder, Professor of Pathology and Laboratory Medicine, and Director of Microbiology and Molecular Diagnostics, University of Louisville Hospital, KY. “The benefits of this AMR panel for predicting antibiotic resistance include the provision of genomic profile data much sooner in about 2.5 hours versus conventional phenotypic information which can take 1-4 days, supports the goal of antimicrobial stewardship, institution of infection control and prevention measures, and alerts the provider to resistant genes representing nine classes of antibiotics. In this era of “rapid diagnostics”, availability of critical information impacts all phases of the healthcare system and potentially reduces cost. AMR panel is regarded as “state of the art”, genomic-based technology.”

Indiscriminate overuse and misuse of antibiotics are key drivers of dramatically spreading antibiotic resistance, a substantial global health threat. A report recently issued[1] by the Centers for Disease Control and Prevention (CDC) revealed that drug-resistant bacteria cause almost 3 million infections and 35,000 deaths a year in the United States alone, meaning that antibiotic-resistant pathogens cause a serious infection every 11 seconds and a death every 15 minutes.

[1] https://www.cdc.gov/DrugResistance/Biggest-Threats.html

 
 
 

 

By providing a fast and reliable solution for the rapid detection of antimicrobial resistance markers associated with relevant pathogens, we believe the Acuitas® AMR Gene Panel is an essential, indispensable tool for targeted antimicrobial therapy improving patient outcomes, facilitating stringent antibiotic stewardship.

“The Acuitas® AMR Gene Panel is the third molecular diagnostic panel that OpGen, as a group, has successfully received clearance for from the FDA,” commented Johannes Bacher, Chief Operating Officer of OpGen. “Along with the Unyvero® LRT and LRT BAL Application Cartridges, OpGen’s rapid testing solutions offer what we believe are the most comprehensive multiplex molecular panels for the rapid diagnosis of antimicrobial resistance in bacteria and fungi associated with life threatening infectious disease.”

“We expect that the clearance of our Acuitas® AMR Gene Panel will expand the total addressable market for this product in the U.S.,” said Oliver Schacht, PhD, President and CEO of OpGen. “It will provide us with substantial opportunities to grow our business in detecting AMR in life-threatening infections since rapid detection of antimicrobial resistance in both surveillance and diagnostic settings is still a major challenge for the clinical lab. Moreover, by providing laboratorians and clinicians with a powerful diagnostic tool to identify resistance earlier, faster and more reliably, the Acuitas® AMR Gene Panel is expected to support antibiotic stewardship efforts to avoid the unnecessary use of antibiotics.”

With commercial launch preparations well advanced, the Company expects to swiftly make the Acuitas® AMR Gene Panel for isolates broadly available to U.S. customers.

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero®, Acuitas® AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

 
 
 

Forward-Looking Statements

This press release includes statements regarding OpGen’s Acuitas® AMR Gene Panel for Isolates and clearance with the U.S. FDA. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from financings, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius 
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Joe Green
Edison Group 
jgreen@edisongroup.com

 

 EX-99.2 3 ex99x2.htm EXHIBIT 99.2

Exhibit 99.2

 

 

 

 

OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021

 

·Preliminary Total Revenue for Q3 2021 was approximately $1.2 million
·Cash as of September 30, 2021 was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020
·OpGen concluded search and expects to announce new CFO once appointment has been formalized

 

ROCKVILLE, Md., October 4, 2021 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the third quarter of 2021 was approximately $1.2 million, up from $1.1 million in the third quarter of 2020. Cash as of September 30, 2021 was approximately $25.4 million, an increase from the $13.4 million as of December 31, 2020.

 

The company announced accomplishment of the following key milestones and recent developments in the third quarter as well as 2021 to date:

·OpGen received 510(k) FDA clearance for its Acuitas AMR Gene Panel
·OpGen initiated prospective multicenter clinical trial in the U.S. for the Unyvero UTI application
·OpGen concluded search and expects to announce new CFO once appointment has been formalized
·OpGen announced data from prospective randomized controlled multicenter clinical study using the Unyvero HPN panel for hospitalized patients with suspicion of pneumonia
·OpGen filed a universal shelf registration statement on Form S-3 for up to $ 150 million
·OpGen achieved key milestone in Unyvero A30 RQ development program with 10 systems now available for verification and validation testing which is ongoing
·OpGen subsidiary Ares Genetics completed another project with Sandoz and continued commercial roll-out and growth of the ARESiss isolate sequencing service business

Mr. Schacht commented, “As we continue into the fourth quarter, we are extremely excited by the recent FDA 510(k) clearance of our Acuitas AMR Gene Panel which we believe to have the potential to aid clinicians in the diagnosis of and treatment decision making for patients with severe, life-threatening infections who are suffering from multi drug resistant organisms. We are getting ready for a swift commercial launch of the Acuitas AMR Gene Panel this quarter here in the U.S. We are also in regular dialog with the Chinese NMPA via our strategic partner Beijing Clear Bio. The Chinese NMPA has requested supplemental clinical data to be generated and submitted in China. We are working with our partners to finalize study design and prepare for subsequent study execution in due course, and we anticipate receiving feedback on the submission of the pneumonia application cartridge documents filed with the NMPA thus far. We are also thrilled to have successfully completed the search for our new Chief Financial Officer to join the OpGen team and we anticipate making the announcement upon formalizing the appointment. Together with our board, we are continuing to evaluate alternatives for financing the future growth of OpGen and believe these are steps that will help drive the company forward and on its desired path.”

The preliminary Q3-2021 financial results are estimates prior to the completion of OpGen’s financial closing procedures and review procedures by its external auditors and therefore may be subject to adjustment when the actual results are available.

 

 
 
 

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

Forward-Looking Statements

This press release includes statements regarding OpGen’s third quarter 2021 results and the current business of OpGen. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from our financings, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius 
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Joe Green
Edison Group
jgreen@edisongroup.com

 

 GRAPHIC 4 image_002.jpg GRAPHIC begin 644 image_002.jpg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end GRAPHIC 5 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 6 opgn-20210930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 opgn-20210930_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 opgn-20210930_pre.xml XBRL PRESENTATION FILE XML 9 opgen_8k_htm.xml IDEA: XBRL DOCUMENT 0001293818 2021-09-30 2021-09-30 iso4217:USD shares iso4217:USD shares 0001293818 false 8-K 2021-09-30 OpGen, Inc. DE 001-37367 06-1614015 9717 Key West Ave Suite 100 Rockville MD 20850 240 813-1260 false false false false Common Stock OPGN NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Sep. 30, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 30, 2021
Entity File Number 001-37367
Entity Registrant Name OpGen, Inc.
Entity Central Index Key 0001293818
Entity Tax Identification Number 06-1614015
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9717 Key West Ave
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 240
Local Phone Number 813-1260
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OPGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://opgen__com/role/Cover Cover Cover 1 false false All Reports Book All Reports opgen_8k.htm ex99x1.htm ex99x2.htm opgn-20210930.xsd opgn-20210930_lab.xml opgn-20210930_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "opgen_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "opgen_8k.htm" ] }, "labelLink": { "local": [ "opgn-20210930_lab.xml" ] }, "presentationLink": { "local": [ "opgn-20210930_pre.xml" ] }, "schema": { "local": [ "opgn-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "OPGN", "nsuri": "http://opgen__com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "opgen_8k.htm", "contextRef": "From2021-09-30to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://opgen__com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "opgen_8k.htm", "contextRef": "From2021-09-30to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://opgen__com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001079973-21-000999-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-21-000999-xbrl.zip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end